NPI: 1417432840 · CHARLOTTE, NC 28210 · General Acute Care Hospital · NPI assigned 10/02/2018
Authorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
| Authorized Official | DEFURIO, ANTHONY (EXECUTIVE VICE PRESIDENT/CFO) |
| NPI Enumeration Date | 10/02/2018 |
Other providers sharing the same authorized official: DEFURIO, ANTHONY
| Year | Claims | Total Paid |
|---|---|---|
| 2019 | 69,596 | $2.52M |
| 2020 | 51,370 | $1.97M |
| 2021 | 69,124 | $3.27M |
| 2022 | 72,284 | $4.01M |
| 2023 | 59,547 | $4.28M |
| 2024 | 59,486 | $4.06M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 30,730 | 28,824 | $4.64M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 29,825 | 27,419 | $3.77M |
| J3490 | Unclassified drugs | 30,193 | 14,096 | $2.55M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 8,025 | 7,531 | $969K |
| 80053 | Comprehensive metabolic panel | 19,613 | 17,423 | $925K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11,811 | 10,612 | $870K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 13,193 | 6,383 | $773K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 2,529 | 1,922 | $574K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1,637 | 1,507 | $521K |
| 80048 | Basic metabolic panel (calcium, ionized) | 8,539 | 6,981 | $502K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3,476 | 2,798 | $294K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2,746 | 2,409 | $285K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2,878 | 2,738 | $282K |
| J8597 | Antiemetic drug, oral, not otherwise specified | 1,155 | 1,080 | $180K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2,075 | 1,918 | $165K |
| 87070 | 1,158 | 1,118 | $165K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 803 | 748 | $129K |
| 71046 | Radiologic examination, chest; 2 views | 6,690 | 6,272 | $127K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 4,714 | 4,367 | $123K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 10,747 | 9,337 | $121K |
| J8540 | Dexamethasone, oral, 0.25 mg | 1,074 | 1,028 | $114K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1,668 | 1,505 | $110K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 232 | 223 | $106K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 817 | 761 | $100K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 765 | 663 | $95K |
| G0378 | Hospital observation service, per hour | 2,801 | 2,291 | $94K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 18,946 | 16,587 | $91K |
| 81025 | 7,737 | 7,107 | $90K | |
| 87081 | 1,108 | 1,065 | $89K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4,123 | 3,239 | $83K |
| 81003 | 6,533 | 5,979 | $69K | |
| 82962 | 3,142 | 1,859 | $67K | |
| 70450 | Computed tomography, head or brain; without contrast material | 1,974 | 1,803 | $62K |
| 85027 | 9,406 | 8,200 | $61K | |
| 87486 | 311 | 303 | $60K | |
| 87210 | 1,594 | 1,487 | $57K | |
| 81001 | 6,478 | 5,944 | $56K | |
| 84702 | 1,911 | 1,697 | $54K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 340 | 186 | $53K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 10,337 | 9,148 | $52K |
| 71045 | Radiologic examination, chest; single view | 3,029 | 2,738 | $32K |
| J1644 | Injection, heparin sodium, per 1000 units | 83 | 36 | $31K |
| 73630 | 369 | 350 | $30K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 145 | 100 | $29K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1,269 | 1,096 | $28K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2,558 | 2,368 | $26K |
| S0028 | Injection, famotidine, 20 mg | 212 | 183 | $24K |
| 59025 | Fetal non-stress test | 1,919 | 1,450 | $24K |
| 81002 | 1,312 | 1,163 | $20K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 1,914 | 1,625 | $14K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 890 | 842 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,738 | 1,608 | $14K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,643 | 2,437 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 569 | 513 | $13K |
| 73610 | 165 | 158 | $12K | |
| 87430 | 977 | 938 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 858 | 794 | $12K |
| 84484 | 6,980 | 5,636 | $12K | |
| 76830 | Ultrasound, transvaginal | 507 | 482 | $12K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2,141 | 1,859 | $11K |
| 73130 | 97 | 90 | $10K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 324 | 311 | $9K |
| 93975 | 866 | 816 | $9K | |
| A9270 | Non-covered item or service | 14,951 | 1,989 | $8K |
| 93971 | 349 | 328 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 54 | 53 | $7K |
| 73560 | 130 | 125 | $7K | |
| 81000 | 630 | 584 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | 15 | 12 | $7K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 506 | 466 | $6K |
| 83690 | 5,445 | 4,870 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1,941 | 1,392 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,193 | 1,151 | $5K |
| 83735 | 5,007 | 4,270 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 91 | 84 | $5K |
| 74018 | 85 | 81 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 6,474 | 5,305 | $5K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 17 | 12 | $5K |
| 73110 | 40 | 38 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 657 | 564 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 26 | 25 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 1,415 | 1,194 | $3K |
| 86900 | 29 | 28 | $3K | |
| 86901 | 646 | 576 | $3K | |
| 73562 | 58 | 52 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 54 | 44 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 372 | 332 | $2K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 88 | 84 | $2K |
| 83880 | 1,764 | 1,568 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,416 | 1,129 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | 13 | 12 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 17 | 14 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,695 | 1,566 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 27 | 26 | $2K |
| 76801 | 49 | 41 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2,978 | 2,156 | $2K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 81 | 73 | $2K |
| 0011A | 22 | 22 | $1K | |
| 87581 | 311 | 303 | $1K | |
| 73030 | 26 | 25 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 1,369 | 1,040 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 4,980 | 4,330 | $1K |
| 82803 | 311 | 280 | $1K | |
| 0012A | 19 | 19 | $1K | |
| 72100 | 43 | 38 | $976.86 | |
| 87077 | 39 | 36 | $907.04 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 6,727 | 5,457 | $861.66 |
| 83605 | 2,180 | 1,884 | $835.46 | |
| 96376 | 2,321 | 1,612 | $797.73 | |
| J2704 | Injection, propofol, 10 mg | 1,596 | 1,473 | $786.97 |
| 72125 | Computed tomography, cervical spine; without contrast material | 70 | 66 | $766.97 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 151 | 133 | $743.41 |
| 85610 | 804 | 641 | $707.74 | |
| 84443 | Thyroid stimulating hormone (TSH) | 826 | 753 | $649.14 |
| 80076 | 421 | 365 | $580.96 | |
| 80143 | 35 | 31 | $451.43 | |
| 80179 | 35 | 31 | $335.96 | |
| Q3014 | Telehealth originating site facility fee | 48 | 42 | $291.51 |
| J7999 | Compounded drug, not otherwise classified | 27 | 16 | $273.09 |
| 94761 | 373 | 287 | $260.87 | |
| 85379 | 865 | 804 | $248.17 | |
| 76937 | 124 | 110 | $241.62 | |
| 82248 | 261 | 237 | $131.02 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 570 | 463 | $104.80 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 137 | 66 | $99.79 |
| 99199 | Unlisted special service, procedure or report | 18 | 18 | $95.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 77 | 68 | $80.59 |
| 87088 | 116 | 110 | $80.20 | |
| 82550 | 106 | 98 | $74.77 | |
| 94760 | 538 | 406 | $59.78 | |
| 85007 | 30 | 26 | $55.42 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 20 | 12 | $31.84 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 94 | 88 | $29.36 |
| 83036 | Hemoglobin; glycosylated (A1C) | 97 | 84 | $28.14 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 786 | 601 | $23.03 |
| 87186 | 131 | 119 | $9.90 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 221 | 187 | $0.23 |
| 84100 | 49 | 28 | $0.00 | |
| 80061 | Lipid panel | 45 | 39 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 63 | 49 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 152 | 52 | $0.00 |
| 97161 | 18 | 12 | $0.00 | |
| 87040 | 230 | 194 | $0.00 | |
| 86850 | 28 | 27 | $0.00 | |
| 36410 | 15 | 13 | $0.00 | |
| 87147 | 49 | 49 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 38 | 36 | $0.00 |
| 81015 | 25 | 24 | $0.00 | |
| 91301 | 41 | 41 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 17 | 12 | $0.00 |